Navigation Links
Symmetry Medical Reports Preliminary Third Quarter Revenue
Date:11/7/2007

WARSAW, Ind., Nov. 7 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), an independent provider of products to the global orthopedic device industry and other medical markets, today reported preliminary third quarter 2007 revenue of $76.5 million.

The Company stated that its Audit Committee's review of the accounting irregularities uncovered at its Sheffield UK facility, which was announced October 4, 2007, is continuing.

Brian Moore, President and Chief Executive Officer, stated, "We are pleased with the current health of the orthopedic markets and the corresponding increase to both large programs and our capacity utilization. We believe we are in an excellent position to meet this higher demand following our strategic decision to maintain our infrastructure during periods of slower growth. We are pleased with our acquisitions and the cross selling opportunities that they continue to generate. The new Malaysian facility is on schedule and we believe will play a key role in servicing the Asian market."

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.

Forward-Looking Statements

Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to: the loss of one or more customers; the development of new products or product innovations by our competitors; product liability; changes in management; changes in conditions effecting the economy, orthopedic device manufacturers or the medical device industry generally; and changes in government regulation of medical devices and third-party reimbursement practices. We refer you to the "Risk Factors" and "Forward Looking Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at http://www.sec.gov.

Investors/Media: Contact:

The Ruth Group Symmetry Medical Inc.

Nick Laudico/Jason Rando Fred L. Hite

(646) 536-7030/7025 Senior Vice President

nlaudico@theruthgroup.com Chief Financial Officer

jrando@theruthgroup.com (574) 371-2218


'/>"/>
SOURCE Symmetry Medical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
2. Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7, 2007
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
5. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Globus Medical Announces Record 2nd Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):